Red Ridge Bio

RedRidge Bio is a clinical-stage biotech company specializing in the discovery and development of biparatopic antibodies (BPAs) — antibodies that simultaneously target two distinct epitopes on a single protein — for cancer and autoimmune diseases. The company's lead assets include biparatopic antibody-drug conjugates for liquid and solid tumors, as well as tissue-tethered immune cell modulators for inflammatory diseases. RedRidge Bio combines high-throughput screening, structural biology, and disease biology expertise to engineer best-in-class therapeutics with superior efficacy and long-term safety profiles.